The DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance
Abstract
An important complication of insulin-resistant states, such as obesity and type 2 diabetes, is an atherogenic dyslipidemia profile characterized by hypertriglyceridemia, low plasma high-density lipoproteins (HDL) cholesterol and a small, dense low-density lipoprotein (LDL) particle profile. The physiological basis of this metabolic dyslipidemia appears to be hepatic overproduction of apoB-containing very low-density lipoprotein (VLDL) particles. This has focused attention on the mechanisms that regulate VLDL secretion in insulin-resistant states. Recent studies in animal models of insulin resistance, particularly the fructose-fed hamster, have enhanced our understanding of these mechanisms, and certain key factors have recently been identified that play important roles in hepatic insulin resistance and dysregulation of the VLDL secretory process. This review focuses on these recent developments as well as on the hypothesis that an interaction between enhanced flux of free fatty acids from peripheral tissues to liver, chronic up-regulation of de novo lipogenesis by hyperinsulinemia and attenuated insulin signaling in the liver may be critical to the VLDL overproduction state observed in insulin resistance. It should be noted that the focus of this review is on molecular mechanisms of the hypertriglyceridemic state associated with insulin resistance and not that observed in association with insulin deficiency (e.g., in streptozotocin-treated animals), which appears to have a different etiology and is related to a catabolic defect rather than secretory overproduction of triglyceride-rich lipoproteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under physiological conditions, insulin represses ApoB synthesis, MTP expression, and VLDL-TG and ApoB secretion via the INSR-IRS-PI3K pathway and related mechanisms, such as protein tyrosine phosphatase 1B (PTP1B) and PTEN [2,107,108].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [107]
In the citing paper
“Normal activity of microsomal triglyceride transfer protein (MTP) is required for the assembly of ApoB lipoproteins [107].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [107]
In the citing paper
“Increased FFA flux, as observed in IR states, has been suggested to increase intracellular availability of TG and indirectly stimulate the assembly and secretion of VLDL particles [12,107,109].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [107]
In the citing paper
“The increase in VLDL-TG production under IR conditions appears to result from decreased sensitivity to the inhibitory effects of insulin on VLDL secretion (Fig. 2) [2,107].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [107]
Citations
Cites
Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A. L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C.-C., et al. (1999) · Science · doi:10.1126/science.283.5407.1544 · Cited by 2,210
Disruption of IRS-2 causes type 2 diabetes in mice
Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J.-M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., et al. (1998) · Nature · doi:10.1038/36116 · Cited by 1,775
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene
Araki, E., Lipes, M. A., Patti, M.-E., Brüning, J. C., Haag III, B., Johnson, R. S., & Kahn, C. R. (1994) · Nature · doi:10.1038/372186a0 · Cited by 1,252
Pathophysiology of insulin resistance in human disease
Reaven, G. M. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.473 · Cited by 1,226
Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1
Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., et al. (1994) · Nature · doi:10.1038/372182a0 · Cited by 1,083
SHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855
Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
Virkamäki, A., Ueki, K., & Kahn, C. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6609 · Cited by 854
Reaven, G. M., Chen, Y. D., Jeppesen, J., Maheux, P., & Krauss, R. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116541 · Cited by 690
Early neonatal death in mice homozygous for a null allele of the insulin receptor gene
Accili, D., Drago, J., Lee, E. J., Johnson, M. D., Cool, M. H., Salvatore, P., Asico, L. D., José, P. A., Taylor, S. I., & Westphal, H. (1996) · Nature Genetics · doi:10.1038/ng0196-106 · Cited by 595
Research works printed but not linked: 1
- Chan, 2000, Apolipoprotein B, Recent Prog Horm Res, 55, 93
Cited by
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,093
Self-citationNguyen, P., Leray, V., Diez, M., Serisier, S., Bloc’h, J. L., Siliart, B., & Dumon, H. (2008) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/j.1439-0396.2007.00752.x · Cited by 968
Is visceral obesity the cause of the metabolic syndrome?
Després, J. (2006) · Annals of Medicine · doi:10.1080/07853890500383895 · Cited by 651
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Hansel, B., Giral, P., Nobecourt, E., Chantepie, S., Bruckert, E., Chapman, M. J., & Kontush, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0305 · Cited by 477
Metadata
- Authors
- Adeli, K., Taghibiglou, C., Van Iderstine, S. C., & Lewis, G. F.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Adeli, Khosrow
- Venue
- Trends in Cardiovascular Medicine
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 11
- Issue
- 5
- Pages
- 170-176
- ISSN
- 1050-1738 (ISSN-L)
- OpenAlex
- W2034751031
- Cited by
- 194
- References
- 75
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 7 · 2017: 9 · 2016: 9 · 2015: 6 · 2014: 9 · 2013: 10 · 2012: 5
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Trends in Cardiovascular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin resistance, very low density lipoprotein secretion, hypertriglyceridemia, dyslipidemia, hepatic insulin resistance, de novo lipogenesis, hyperinsulinemia, type 2 diabetes, obesity
- MeSH terms
- Animals, Apolipoproteins B, Carrier Proteins, Fatty Acids, Nonesterified, Insulin Resistance, Lipoproteins, VLDL, Liver, Receptor, Insulin, Hypertriglyceridemia, Signal Transduction, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance. https://app.cochat.ai/papers/10.1016/s1050-1738(01)00084-6
- The paper
- Adeli, K., Taghibiglou, C., Van Iderstine, S. C., & Lewis, G. F. (2001). Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance. Trends in Cardiovascular Medicine. https://doi.org/10.1016/s1050-1738(01)00084-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.